Premium
Bile Acids Aspiration Reduces Survival in Lung Transplant Recipients with BOS Despite Azithromycin
Author(s) -
Mertens V.,
Blondeau K.,
Van Oudenhove L.,
Vanaudenaerde B.,
Vos R.,
Farre R.,
Pauwels A.,
Verleden G.,
Van Raemdonck D.,
Sifrim D.,
Dupont L. J.
Publication year - 2011
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2010.03380.x
Subject(s) - medicine , azithromycin , lung , lung transplantation , gastroenterology , intensive care medicine , antibiotics , microbiology and biotechnology , biology
Azithromycin (AZM) improved bronchiolitis obliterans syndrome (BOS) and reduced aspiration in lung transplant (LTx) recipients. We hypothesize that AZM could improve graft and overall survival more efficiently in LTx patients with BOS who have bile acid (BA) aspiration by protecting against the aspiration‐induced progression of BOS. The goal was to compare FEV 1 (% baseline), BOS progression and overall survival in LTx recipients treated with AZM for BOS, both with versus without BA aspiration. Therefore, LTx recipients treated with AZM for BOS were recruited and broncho‐alveolar lavage (BAL) samples were analyzed for the presence of BA and neutrophilia before the start of AZM treatment. Short‐term effect of AZM on FEV 1 and BAL neutrophilia was assessed, progression of BOS and survival were followed‐up for 3 years and results were compared between patients with/without BA aspiration. 19/37 LTx patients had BA in BAL. BA aspiration predisposed to a significantly worse outcome, in terms of decline in FEV 1 , progression of BOS ≥ 1 and survival. AZM does not seem to protect against the long‐term allograft dysfunction caused by gastroesophageal reflux (GER) and aspiration and an additional treatment targeting aspiration may be indicated in those LTx patients.